Published in J Exp Med on April 10, 2006
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20
Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol (2015) 4.25
Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med (2006) 4.17
PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol (2010) 3.51
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood (2010) 3.21
Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood (2009) 2.91
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. JAMA Oncol (2016) 2.79
Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A (2008) 2.73
The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol (2011) 2.69
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev (2011) 2.54
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 2.50
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol (2011) 2.34
Mesenchymal cells of the intestinal lamina propria. Annu Rev Physiol (2011) 2.18
The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat Immunol (2012) 2.17
Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol (2009) 2.15
Mechanisms maintaining peripheral tolerance. Nat Immunol (2009) 2.14
Hepatic microenvironment programs hematopoietic progenitor differentiation into regulatory dendritic cells, maintaining liver tolerance. Blood (2008) 2.02
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol (2010) 1.98
PD-1 as a potential target in cancer therapy. Cancer Med (2013) 1.98
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res (2014) 1.79
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med (2011) 1.77
Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol (2012) 1.71
Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med (2012) 1.71
Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. J Immunol (2011) 1.66
Requirement for interactions of natural killer T cells and myeloid-derived suppressor cells for transplantation tolerance. Am J Transplant (2014) 1.63
FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer (2008) 1.63
Anti-IL-7 receptor-α reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proc Natl Acad Sci U S A (2012) 1.60
IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A (2012) 1.54
PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. J Clin Invest (2010) 1.53
PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol (2009) 1.53
PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol (2007) 1.51
Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology (2012) 1.48
Regulation of T cell activation and tolerance by PDL2. Proc Natl Acad Sci U S A (2006) 1.46
Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood (2013) 1.44
Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci U S A (2017) 1.43
Anti-CD3 treatment up-regulates programmed cell death protein-1 expression on activated effector T cells and severely impairs their inflammatory capacity. Immunology (2017) 1.41
Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev (2009) 1.39
Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in mice. J Clin Invest (2009) 1.37
Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. J Immunol (2009) 1.37
Role of the PD-1 pathway in the immune response. Am J Transplant (2012) 1.35
T-cell costimulation and coinhibition in atherosclerosis. Circ Res (2008) 1.32
Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. Cell Mol Immunol (2006) 1.30
Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol (2011) 1.28
Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc Natl Acad Sci U S A (2007) 1.28
PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE. Eur J Immunol (2008) 1.27
Transforming growth factor-beta suppresses the activation of CD8+ T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunity. Diabetes (2008) 1.25
B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol (2008) 1.25
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer (2015) 1.25
Adoptive transfer of immunomodulatory M2 macrophages prevents type 1 diabetes in NOD mice. Diabetes (2012) 1.25
PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol (2012) 1.24
Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther (2015) 1.23
At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol (2013) 1.21
The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget (2015) 1.20
Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J Clin Invest (2007) 1.19
The role of LAT in increased CD8+ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1. J Virol (2011) 1.18
Circulating CSF-1 promotes monocyte and macrophage phenotypes that enhance lupus nephritis. J Am Soc Nephrol (2009) 1.18
Programmed cell death ligand 2 regulates TH9 differentiation and induction of chronic airway hyperreactivity. J Allergy Clin Immunol (2012) 1.17
Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. J Exp Med (2011) 1.14
PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int Immunol (2010) 1.13
Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection. Immunology (2008) 1.13
PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. Cell Cycle (2012) 1.12
Immune checkpoints in central nervous system autoimmunity. Immunol Rev (2012) 1.11
B7-H1 expression on non-B and non-T cells promotes distinct effects on T- and B-cell responses in autoimmune arthritis. Eur J Immunol (2010) 1.11
PD-1 ligand expression by human colonic myofibroblasts/fibroblasts regulates CD4+ T-cell activity. Gastroenterology (2008) 1.11
T cell and APC dynamics in situ control the outcome of vaccination. J Immunol (2010) 1.11
Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice. J Clin Invest (2010) 1.10
The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J Immunol (2011) 1.10
TLR-mediated induction of negative regulatory ligands on dendritic cells. J Mol Med (Berl) (2008) 1.09
The complex role of B7 molecules in tumor immunology. Trends Mol Med (2008) 1.09
The immunomodulatory glycan LNFPIII initiates alternative activation of murine macrophages in vivo. Immunology (2008) 1.08
Programmed death-1/B7-H1 negative costimulation protects mouse liver against ischemia and reperfusion injury. Hepatology (2010) 1.08
PD-1-dependent mechanisms maintain peripheral tolerance of donor-reactive CD8+ T cells to transplanted tissue. J Immunol (2008) 1.07
Immunity and immune suppression in human ovarian cancer. Immunotherapy (2011) 1.07
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology (2015) 1.06
Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc (2014) 1.06
Ly6C(low) monocytes differentiate into dendritic cells and cross-tolerize T cells through PDL-1. J Immunol (2009) 1.06
CD8+ Tregs in lupus, autoimmunity, and beyond. Autoimmun Rev (2010) 1.04
Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation. J Clin Invest (2010) 1.04
PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes. Diabetes (2013) 1.04
Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J Immunol (2008) 1.03
Lung cancer: Biology and treatment options. Biochim Biophys Acta (2015) 1.02
Sunlight triggers cutaneous lupus through a CSF-1-dependent mechanism in MRL-Fas(lpr) mice. J Immunol (2008) 1.02
PD-1, gender, and autoimmunity. Autoimmun Rev (2010) 1.02
New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci (2015) 1.02
Structural, cellular and molecular aspects of immune privilege in the testis. Front Immunol (2012) 1.01
Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med (2012) 1.00
Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1. Rheumatology (Oxford) (2008) 0.99
Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants. Blood (2011) 0.99
Dendritic cells: a critical player in cancer therapy? J Immunother (2008) 0.99
PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1. J Neuroinflammation (2013) 0.99
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some. Front Immunol (2015) 0.98
Layers of dendritic cell-mediated T cell tolerance, their regulation and the prevention of autoimmunity. Front Immunol (2012) 0.98
Regulatory and conventional CD4+ T cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy. J Immunol (2008) 0.97
Up-regulation of programmed death-1 expression on beryllium-specific CD4+ T cells in chronic beryllium disease. J Immunol (2008) 0.97
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med (1999) 16.91
The B7 family revisited. Annu Rev Immunol (2005) 13.51
PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (2001) 8.31
Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity (1994) 7.22
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol (2004) 7.16
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med (2001) 6.97
The NOD mouse: a model of immune dysregulation. Annu Rev Immunol (2005) 6.71
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol (2001) 5.17
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A (2004) 4.75
B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity (2004) 4.60
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20
An improved method for isolation of mouse pancreatic islets. Transplantation (1985) 3.52
Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol (2003) 3.37
B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice. J Exp Med (1996) 3.35
Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med (2003) 2.94
B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol (1998) 2.63
Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci U S A (1996) 2.53
Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A (2005) 2.49
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation (2002) 2.49
Tumor necrosis factor-alpha regulation of CD4+CD25+ T cell levels in NOD mice. Proc Natl Acad Sci U S A (2002) 2.45
Deletion of a conserved Il4 silencer impairs T helper type 1-mediated immunity. Nat Immunol (2004) 2.38
In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med (2005) 2.28
A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med (2005) 2.13
The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology (2004) 2.02
An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity (2004) 2.00
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med (2003) 1.92
The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity (2004) 1.85
Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest (2004) 1.71
NOD/LtSz-Rag1null mice: an immunodeficient and radioresistant model for engraftment of human hematolymphoid cells, HIV infection, and adoptive transfer of NOD mouse diabetogenic T cells. J Immunol (2000) 1.70
Negative co-receptors on lymphocytes. Curr Opin Immunol (2002) 1.66
The B7/CD28 costimulatory family in autoimmunity. Immunol Rev (2005) 1.57
PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis. Eur J Immunol (2006) 1.38
Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proc Natl Acad Sci U S A (2000) 1.31
Suppressed T-cell activation by IFN-gamma-induced expression of PD-L1 on renal tubular epithelial cells. Nephrol Dial Transplant (2004) 1.22
Immune regulation by novel costimulatory molecules. Immunol Res (2003) 1.07
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
The B7 family revisited. Annu Rev Immunol (2005) 13.51
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol (2008) 10.26
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med (2007) 9.51
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94
Identification of cells initiating human melanomas. Nature (2008) 8.28
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol (2007) 7.60
The B7-CD28 superfamily. Nat Rev Immunol (2002) 7.24
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature (2002) 6.58
Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol (2011) 6.23
Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol (2003) 6.07
Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol (2006) 6.00
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature (2008) 5.94
The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol (2008) 5.92
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A (2004) 4.75
Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol (2003) 4.66
Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest (2004) 4.65
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A (2010) 4.56
TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity (2007) 4.49
Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol (2007) 4.41
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20
Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med (2006) 4.17
Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med (2003) 4.12
Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med (2002) 3.80
PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol (2002) 3.78
CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med (2004) 3.57
ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res (2005) 3.52
PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol (2010) 3.51
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res (2013) 3.48
Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol (2006) 3.42
Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol (2003) 3.37
Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med (2010) 3.32
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res (2013) 3.27
RIAM, an Ena/VASP and Profilin ligand, interacts with Rap1-GTP and mediates Rap1-induced adhesion. Dev Cell (2004) 3.27
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov (2013) 3.25
Tight regulation of memory CD8(+) T cells limits their effectiveness during sustained high viral load. Immunity (2011) 3.19
Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A (2008) 3.14
Delayed graft function in kidney transplantation. Lancet (2004) 3.06
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med (2003) 3.00
CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat Immunol (2008) 2.99
Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology (2008) 2.95
Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol (2003) 2.91
The TIM gene family: emerging roles in immunity and disease. Nat Rev Immunol (2003) 2.90
PD-1 and its ligands in T-cell immunity. Curr Opin Immunol (2007) 2.86
CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J Immunol (2005) 2.83
Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med (2008) 2.81
Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett (2002) 2.80
Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity (2003) 2.80
CD4+ T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism. J Immunol (2003) 2.79
TIM-1 induces T cell activation and inhibits the development of peripheral tolerance. Nat Immunol (2005) 2.77
Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A (2008) 2.73
Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol (2009) 2.70
The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol (2011) 2.69
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog (2009) 2.57
Transplant nephrectomy improves survival following a failed renal allograft. J Am Soc Nephrol (2009) 2.56
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation (2002) 2.49
Interaction of human PD-L1 and B7-1. Mol Immunol (2008) 2.48
Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity (2012) 2.47
A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol (2006) 2.46
Induction of T helper type 1-like regulatory cells that express Foxp3 and protect against airway hyper-reactivity. Nat Immunol (2004) 2.43
Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J Clin Invest (2011) 2.40
Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc Natl Acad Sci U S A (2007) 2.39
Deletion of a conserved Il4 silencer impairs T helper type 1-mediated immunity. Nat Immunol (2004) 2.38
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol (2011) 2.34
PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol (2007) 2.34
Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med (2013) 2.29
Structures of T cell immunoglobulin mucin protein 4 show a metal-Ion-dependent ligand binding site where phosphatidylserine binds. Immunity (2007) 2.29
A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med (2008) 2.26
Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes (2008) 2.25
Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination. J Virol (2007) 2.21